Susquehanna International Group
KALV

Susquehanna International Group’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna International Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$941K Sell
46,760
-25,135
-35% -$405K ﹤0.01% 8023
2025
Q4 		$1.16M Sell
71,895
-321,444
-82% -$4.26M ﹤0.01% 6849
2025
Q3 		$4.79M Buy
393,339
+99,141
+34% +$1.37M ﹤0.01% 4156
2025
Q2 		$3.33M Buy
294,198
+242,030
+464% +$2.96M ﹤0.01% 4753
2025
Q1 		$602K Buy
52,168
+22,990
+79% +$235K ﹤0.01% 8495
2024
Q4 		$247K Buy
29,178
+11,357
+64% +$118K ﹤0.01% 10240
2024
Q3 		$206K Buy
17,821
+4,335
+32% +$54.5K ﹤0.01% 10409
2024
Q2 		$159K Sell
13,486
-6,400
-32% -$74.7K ﹤0.01% 10637
2024
Q1 		$236K Sell
19,886
-7,085
-26% -$94.5K ﹤0.01% 10244
2023
Q4 		$330K Buy
26,971
+16,177
+150% +$147K ﹤0.01% 9630
2023
Q3 		$104K Sell
10,794
-49,177
-82% -$502K ﹤0.01% 10878
2023
Q2 		$540K Buy
59,971
+25,906
+76% +$239K ﹤0.01% 8133
2023
Q1 		$268K Sell
34,065
-73,180
-68% -$546K ﹤0.01% 9971
2022
Q4 		$725K Buy
+107,245
New +$574K ﹤0.01% 6935
2022
Q2 		– Sell
-12,558
Closed -$139K – 13435
2022
Q1 		$185K Sell
12,558
-17,865
-59% -$257K ﹤0.01% 11325
2021
Q4 		$402K Sell
30,423
-10,449
-26% -$166K ﹤0.01% 9761
2021
Q3 		$713K Buy
40,872
+2,819
+7% +$57.1K ﹤0.01% 8455
2021
Q2 		$912K Sell
38,053
-27,967
-42% -$732K ﹤0.01% 8017
2021
Q1 		$1.7M Sell
66,020
-9,563
-13% -$251K ﹤0.01% 6321
2020
Q4 		$1.44M Buy
+75,583
New +$1.3M ﹤0.01% 5840
2019
Q3 		– Sell
-23,514
Closed -$521K – 10512
2019
Q2 		$521K Sell
23,514
-24,546
-51% -$576K ﹤0.01% 7178
2019
Q1 		$1.38M Buy
48,060
+239
+0.5% +$5.18K ﹤0.01% 4387
2018
Q4 		$944K Buy
+47,821
New +$961K ﹤0.01% 4793
2016
Q3 		– Sell
-4,583
Closed -$43K – 8727
2016
Q2 		$43K Buy
+4,583
New +$53.1K ﹤0.01% 8272

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's KALV Position: Q1 2026 in Review

Susquehanna International Group reduced its KalVista Pharmaceuticals (KALV) stake by 35% in Q1 2026, selling an estimated $405K and leaving 46,760 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #8023.

Susquehanna International Group first reported a position in KALV in Q2 2016 and has held it in 24 quarters since. The position peaked at $4.79M in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Susquehanna International Group held 46,760 shares of KalVista Pharmaceuticals worth $941K as of Q1 2026.
  • Susquehanna International Group sold 25,135 KalVista Pharmaceuticals shares in Q1 2026, an estimated $405K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8023 holding.
  • Susquehanna International Group first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 24 quarters since.
  • Susquehanna International Group's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.